Melkart (Vildagliptin)

Vildagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels after meals and throughout the day.

The dosage of Melkart is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for vildagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Melkart, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melkart (vildagliptin) shares the same mechanism of action as other DPP‑4 inhibitors such as sitagliptin or linagliptin. Clinical studies show comparable efficacy in lowering HbA1c, while differences may exist in dosing frequency, renal adjustment requirements, and individual safety profiles, which clinicians consider when selecting therapy.

Melkart tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Melkart is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

The most serious adverse events linked to vildagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic response.

Melkart is contraindicated in patients with a known hypersensitivity to vildagliptin or any of the tablet’s excipients. It should be used with caution, or avoided, in individuals with severe renal impairment, active pancreatitis, or those who are pregnant or breastfeeding without a clear medical justification.